Patent US6120773A successfully refreshed from Google Patents.
US6120773A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Recombinant herpes simplex viruses vaccines and methods
Assignee: Arch Development Corp
•
Filing: 1994-07-08
•
Granted: 2000-09-19
•
Expires: 2014-07-08
Abstract
Abstract A recombinant herpes simplex virus genome having modified gamma 134.5 genes incapable of expressing an active ICP34.5 gene product, vaccines comprising the recombinant herpes simplex virus genome methods for immunizing a host against the herpes simplex virus using the recombinant herpes simplex virus genome, and a method for preparing the vaccine are disclosed.
Inventors
- 👤 Bernard Roizman
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-07 09:34
CPC Classifications
C; C12; C12N; C12N15/00; C12N15/09; C12N15/63; C12N15/79; C12N15/85; C12N15/86; A; A61; A61K; A61K39/00; A61K39/12; A61P; A61P31/00; A61P31/12; A61P31/20; A61P31/22; C07; C07K; C07K14/00; C07K14/005; A61K39/245; C12N2710/00; C12N2710/00011; C12N2710/16011; C12N2710/16611; C12N2710/16622; C12N2710/16634; C12N2710/16641; C12N2710/16643
Claims Analysis
Total Claims: 32
Claim 1
Independent Claim
48 words
A recombinant herpes simplex virus genome having modified γ 1 34.5 genes incapable of expressing an active ICP34.5 gene product, wherein the modification is selected from the group consisting of insertions, substitutions, and deletions wherein the deletions have at least one terminus within the γ 1 34.5 genes.
Claim 2
Dependent Claim
48 words
A recombinant herpes simplex virus genome having modified γ 1 34.5 genes incapable of expressing an active ICP34.5 gene product, wherein the modification is selected from the group consisting of insertions, substitutions, and deletions wherein the deletions have at least one terminus within the γ 1 34.5 genes.
Claim 3
Dependent Claim
39 words
The herpes simplex virus genome of claim 1 wherein each said γ 1 34.5 gene comprises a stop codon in reading frame between a first and a last codon of a coding sequence of said γ 1 34.5 gene.
Claim 4
Dependent Claim
33 words
The herpes simplex virus genome of claim 2 wherein said virus is HSV-1(F) and at least one said γ 1 34.5 gene comprises said stop codon at a BstEII restriction endonuclease site therein.
Claim 5
Dependent Claim
21 words
The herpes simplex virus genome of claim 1 wherein at least one modified γ 1 34.5 gene comprises a deletion mutation.
Claim 6
Dependent Claim
35 words
The herpes simplex virus genome of claim 4 wherein said herpes simplex virus genome is HSV-1(F) and said deletion mutation comprises a portion of a coding sequence between BstEII and StuI restriction endonuclease sites therein.
Claim 7
Dependent Claim
13 words
The herpes simplex virus genome of claim 1 wherein said virus is HSV-1.
Claim 8
Dependent Claim
13 words
The herpes simplex virus genome of claim 1 wherein said virus is HSV-2.
Claim 9
Dependent Claim
58 words
A vaccine comprising a herpes simplex virus genome having modified γ 1 34.5 genes incapable of expressing an active ICP34.5 gene product, and a pharmaceutically acceptable diluent, adjuvant or carrier, wherein the modification is selected from the group consisting of insertions, substitutions, and deletions wherein the deletions have at least one terminus within the γ 1 34.5 genes.
Claim 10
Dependent Claim
58 words
A vaccine comprising a herpes simplex virus genome having modified γ 1 34.5 genes incapable of expressing an active ICP34.5 gene product, and a pharmaceutically acceptable diluent, adjuvant or carrier, wherein the modification is selected from the group consisting of insertions, substitutions, and deletions wherein the deletions have at least one terminus within the γ 1 34.5 genes.
Claim 11
Dependent Claim
36 words
The vaccine of claim 8 wherein each said γ 1 34.5 gene comprises a stop codon in reading frame between a first and a last codon of a coding sequence of said γ 1 34.5 gene.
Claim 12
Dependent Claim
30 words
The vaccine of claim 4 wherein said virus is HSV-1(F) and at least one said γ 1 34.5 gene comprises said stop codon at a BstEII restriction endonuclease site therein.
Claim 13
Dependent Claim
18 words
The vaccine of claim 8 wherein at least one said γ 1 34.5 gene comprises a deletion mutation.
Claim 14
Dependent Claim
29 words
The vaccine of claim 11 wherein said virus is HSV-1(F) and said deletion mutation comprises a portion of a coding sequence between BstEII and StuI restriction endonuclease sites therein.
Claim 15
Dependent Claim
10 words
The vaccine of claim 8 wherein said virus is HSV-1.
Claim 16
Dependent Claim
10 words
The vaccine of claim 8 wherein said virus is HSV-2.
Claim 17
Independent Claim
81 words
A method of immunizing a host against a herpes simplex virus comprising the step of inoculating said host with an immunity-inducing dose of a vaccine comprising a herpes simplex virus genome having modified γ 1 34.5 genes incapable of expressing an active ICP34.5 gene product and a pharmaceutically acceptable diluent, adjuvant, or carrier, wherein the modification is selected from the group consisting of insertions, substitutions, and deletions wherein the deletions have at least one terminus within the γ 1 34.5 genes.
Claim 18
Independent Claim
81 words
A method of immunizing a host against a herpes simplex virus comprising the step of inoculating said host with an immunity-inducing dose of a vaccine comprising a herpes simplex virus genome having modified γ 1 34.5 genes incapable of expressing an active ICP34.5 gene product and a pharmaceutically acceptable diluent, adjuvant, or carrier, wherein the modification is selected from the group consisting of insertions, substitutions, and deletions wherein the deletions have at least one terminus within the γ 1 34.5 genes.
Claim 19
Dependent Claim
36 words
The method of claim 15 wherein each said γ 1 34.5 gene has a stop codon in reading frame between a first and a last codon of a coding sequence of said γ 1 34.5 gene.
Claim 20
Dependent Claim
30 words
The method of claim 16 wherein said virus is HSV-1(f) and at least one said γ 1 34.5 gene comprises said stop codon at a BstEII restriction endonuclease site therein.
Claim 21
Dependent Claim
18 words
The method of claim 15 wherein at least one modified γ 1 34.5 gene comprises a deletion mutation.
Claim 22
Dependent Claim
29 words
The method of claim 18 wherein said virus is HSV-1(F) and said deletion mutation comprises a portion of a coding sequence between BstEII and StuI restriction endonuclease sites therein.
Claim 23
Dependent Claim
10 words
The method of claim 15 wherein said virus is HSV-1.
Claim 24
Dependent Claim
10 words
The method of claim 15 wherein said virus is HSV-2.
Claim 25
Independent Claim
73 words
A method of preparing a vaccine comprising the steps of: modifying the γ 1 34.5 genes of a herpes simplex virus, to render said genes incapable of expressing an active ICP34.5 gene product; and combining said virus with a pharmaceutically acceptable diluent, adjuvant, or carrier, wherein the modification is selected from the group consisting of insertions, substitutions, and deletions wherein the deletions have at least one terminus within the γ 1 34.5 genes.
Claim 26
Independent Claim
73 words
A method of preparing a vaccine comprising the steps of: modifying the γ 1 34.5 genes of a herpes simplex virus, to render said genes incapable of expressing an active ICP34.5 gene product; and combining said virus with a pharmaceutically acceptable diluent, adjuvant, or carrier, wherein the modification is selected from the group consisting of insertions, substitutions, and deletions wherein the deletions have at least one terminus within the γ 1 34.5 genes.
Claim 27
Dependent Claim
37 words
The method of claim 22 wherein said modifying step comprises the step of inserting a stop codon in reading frame between a first and a last codon of a coding sequence of said γ 1 34.5 genes.
Claim 28
Dependent Claim
35 words
The method of claim 23 wherein said virus is HSV-1(F) and said inserting step comprises the step of introducing a stop codon at a BstEII restriction endonuclease site in the γ 1 34.5 genes thereof.
Claim 29
Dependent Claim
22 words
The method of claim 22 wherein said modifying step comprises the step of deleting a portion of said γ 1 34.5 genes.
Claim 30
Dependent Claim
33 words
The method of claim 25 wherein said virus is HSV-1(F) and said deleting step comprises the step of deleting a portion of a coding sequence between BstEII and StuI restriction endonuclease sites therein.
Claim 31
Dependent Claim
10 words
The method of claim 22 wherein said virus is HSV-1.
Claim 32
Dependent Claim
10 words
The method of claim 22 wherein said virus is HSV-2.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2003-09-19 | 2004-03-20 | 2004-09-19 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2007-09-19 | 2008-03-20 | 2008-09-19 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2011-09-19 | 2012-03-20 | 2012-09-19 | $7700.00 | Window Closed / Lapsed |